Susquehanna International Group, LLP Seres Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.48 $15,609 - $33,004	-22,300 Reduced 6.66%	312,500 $296,000
Q2 2024 Aug 15, 2024	BUY	$0.56 - $1.19 $30,128 - $64,022	53,800 Added 19.15%	334,800 $241,000
Q1 2024 May 07, 2024	BUY	$0.75 - $1.56 $178,875 - $372,060	238,500 Added 561.18%	281,000 $216,000
Q4 2023 Feb 14, 2024	BUY	$0.93 - $2.15 $11,718 - $27,090	12,600 Added 42.14%	42,500 $59,000
Q3 2023 Nov 14, 2023	SELL	$2.33 - $5.07 $452,719 - $985,101	-194,300 Reduced 86.66%	29,900 $71,000
Q2 2023 Aug 11, 2023	BUY	$4.67 - $6.55 $840,133 - $1.18 Million	179,900 Added 406.09%	224,200 $1.07 Million
Q1 2023 May 16, 2023	BUY	$4.95 - $6.09 $50,985 - $62,727	10,300 Added 30.29%	44,300 $251,000
Q4 2022 Feb 14, 2023	SELL	$5.09 - $9.05 $414,326 - $736,670	-81,400 Reduced 70.54%	34,000 $190,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $350 - $720	-100 Reduced 0.09%	115,400 $741,000

40.5M

304K

471K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $114M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.